Home › Endometrial Cancer
Endometrial Cancer clinical trials recruiting in the U.S.
171 studies for Endometrial Cancer are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX69 studies
- New York City, NY54 studies
- Boston, MA51 studies
- Arlington, VA41 studies
- Nashville, TN38 studies
- Los Angeles, CA35 studies
- St. Louis, MO29 studies
- Philadelphia, PA29 studies
- Oklahoma City, OK28 studies
- San Antonio, TX27 studies
- Queens, NY26 studies
- Dallas, TX25 studies
- Pittsburgh, PA24 studies
- Columbus, OH24 studies
- Portland, OR24 studies
- Detroit, MI23 studies
- Chicago, IL23 studies
- Edison, NJ20 studies
- Minneapolis, MN20 studies
- Orlando, FL20 studies
- Washington, DC20 studies
- Rochester, MN19 studies
- Cleveland, OH19 studies
- Durham, NC19 studies
- Grand Rapids, MI18 studies
- Seattle, WA18 studies
- Baldwin Park, CA17 studies
- Atlanta, GA17 studies
- Birmingham, AL16 studies
- San Francisco, CA16 studies
- Miami, FL16 studies
- Aurora, CO16 studies
- Tampa, FL15 studies
- Austin, TX15 studies
- Denver, CO15 studies
- Charlottesville, VA15 studies
- Salt Lake City, UT15 studies
- New Haven, CT15 studies
- San Diego, CA15 studies
- Providence, RI14 studies
By state
- Alabama19 studies
- Alaska4 studies
- Arizona22 studies
- Arkansas11 studies
- California73 studies
- Colorado32 studies
- Connecticut22 studies
- Delaware4 studies
- District of Columbia12 studies
- Florida63 studies
- Georgia24 studies
- Hawaii3 studies
- Idaho4 studies
- Illinois35 studies
- Indiana17 studies
- Iowa10 studies
- Kansas5 studies
- Kentucky10 studies
- Louisiana14 studies
- Maine6 studies
- Maryland22 studies
- Massachusetts54 studies
- Michigan45 studies
- Minnesota42 studies
- Mississippi5 studies
- Missouri31 studies
- Montana5 studies
- Nebraska10 studies
- Nevada10 studies
- New Jersey32 studies
- New Mexico13 studies
- New York69 studies
- North Carolina34 studies
- North Dakota6 studies
- Ohio49 studies
- Oklahoma30 studies
- Oregon27 studies
- Pennsylvania46 studies
- Rhode Island14 studies
- South Carolina9 studies
- South Dakota11 studies
- Tennessee40 studies
- Texas95 studies
- Utah26 studies
- Virginia57 studies
- Washington24 studies
- West Virginia4 studies
- Wisconsin24 studies
Recently updated studies
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
RecruitingPhase 1
Ages 18 and older · Women · Updated Nov 13, 2026 · NCT06964009Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT05112601A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
RecruitingPhase 1
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT07664735A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06270706A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
RecruitingPhase 1
Ages 16 and older · All sexes · Updated Nov 12, 2026 · NCT07197554Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT04683653Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RecruitingPhase 2
Ages 18 to 72 · All sexes · Updated Nov 12, 2026 · NCT01174121Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
RecruitingPhase 1
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT05950464A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07458347Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
All ages · All sexes · Updated Nov 12, 2026 · NCT05564377Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT05640999A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT06340568A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07020221A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT06952504A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07503808A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06515613Improving Rural Endometrial Cancer Care
Recruiting
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT07927244Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 6, 2026 · NCT07198074A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Nov 5, 2026 · NCT06586957Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07867002Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Nov 5, 2026 · NCT06253494Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
RecruitingObservational study
Ages 18 and older · Women · Updated Nov 5, 2026 · NCT05051722cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Nov 4, 2026 · NCT05366881Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06400472From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.